GGrantIndex
← Search

Microchemical Core Facility

$335,359P30FY2009CANIH

University Of Southern California, Los Angeles CA

Investigators

Linked publications, trials & patents

Trial NCT07456436Trial NCT07339254Trial NCT07332312Trial NCT07312162Trial NCT07306338Trial NCT07279571Trial NCT07276048Trial NCT07259304Trial NCT07229443Trial NCT07186699Trial NCT07162194Trial NCT07082257Trial NCT07076147Trial NCT06500169Trial NCT06422455Trial NCT06420219Trial NCT06374251Trial NCT06338657Trial NCT06336928Trial NCT06336902Trial NCT06297265Trial NCT06191575Trial NCT06171607Trial NCT06132087Trial NCT06128525Trial NCT06067295Trial NCT06063928Trial NCT06063486Trial NCT06060873Trial NCT05989828Trial NCT05791448Trial NCT05786664Trial NCT05516485Trial NCT05514990Trial NCT05462561Trial NCT05340309Trial NCT04981834Trial NCT04941430Trial NCT04927559Trial NCT04832763Trial NCT04830735Trial NCT04752267Trial NCT04387084Trial NCT04387071Trial NCT04373044Trial NCT04318028Trial NCT04315701Trial NCT04162678Trial NCT03971266Trial NCT03921047Trial NCT03858205Trial NCT03789773Trial NCT03739801Trial NCT03698162Trial NCT03657641Trial NCT03594448Trial NCT03576963Trial NCT03568292Trial NCT03568266Trial NCT03563651Trial NCT03563352Trial NCT03552796Trial NCT03537690Trial NCT03519984Trial NCT03514927Trial NCT03492801Trial NCT03485794Trial NCT03412370Trial NCT03408561Trial NCT03353896Trial NCT03348137Trial NCT03344211Trial NCT03330821Trial NCT03300609Trial NCT03300401Trial NCT03284346Trial NCT03267680Trial NCT03257761Trial NCT03238664Trial NCT03234556Trial NCT03207854Trial NCT03176979Trial NCT03146871Trial NCT03137706Trial NCT03120390Trial NCT03111823Trial NCT03098277Trial NCT03092856Trial NCT03091842Trial NCT03091816Trial NCT03091803Trial NCT03057639Trial NCT03049618Trial NCT03042897Trial NCT02978846Trial NCT02970617Trial NCT02970045Trial NCT02968680Trial NCT02967380Trial NCT02960308

Abstract

The objectives of the Microchemical Core Laboratory are to provide Cancer Center members with: 1) DMA sequencing - the sequence of bases is determined by separating truncated fluorescent dideoxy-labeled products and reads of over 1,000 bases are routinely provided; 2) DMA synthesis - small segments of DMA are synthesized, particularly molecules greater than 40 and up to 130 bases in length, modified oligos difficult or impossible to obtain commercially, as well as siRNA pairs for expression studies; 3) Protein sequencing - the sequence of amino acids in a protein chain is determined by removing amino acids, one at a time from one end (amino) using Edman chemistry and identifying each amino acid derivative by HPLC. These services are faster and cheaper, or are even unobtainable, from corporate businesses. Furthermore, researchers can seek advice in the design of products and instruction in the preparation of samples that acce erate the successful execution of experiments. The ready availability of these technologies enables Cancer Center members, whether basic or clinical researchers, to rapidly bring the power of molecular biology to bear on attacking the fundamental problems of cancer, as well as translating these discoveries for use in the clinic.

View original record on NIH RePORTER →